| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780026 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
Patients diagnosed with dysgerminoma have an excellent OS, across all ages, even in the context of metastatic disease. Data from three large CTOs supports the investigation of carboplatin-based regimens in the frontline treatment of all patients with advanced-stage dysgerminoma to minimize treatment-related toxicities.
Keywords
β-HCGFIGOAYAGCTBEPU.S.EFsSMNalpha-fetoproteinU.K.United StatesEvent-free survivaloverall survivalAFPMalignant ovarian germ cell tumorGerm cell tumorJEBVersusvs.yearsMagicInternational Federation of Gynecology and Obstetricslactate dehydrogenaseLDHSecond malignant neoplasmadolescent and young adultUnited KingdomGynecologic Oncology GroupChildren's Oncology Groupbeta-human chorionic gonadotropin
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rachana Shah, Caihong Xia, Mark Krailo, James F. Amatruda, Suren G. Arul, Deborah F. Billmire, William E. Brady, Allan Covens, David M. Gershenson, Juliet P. Hale, Jean Hurteau, Matthew J. Murray, James C. Nicholson, Thomas A. Olson, Farzana Pashankar,